<Following publication of this article, the authors became aware of an error regarding the effect alleles for genetic variants associated with circulating FGF21. The effect alleles for genetic variants associated with circulating FGF21 were misaligned. The effect allele (EA) for rs1260326 and rs2548957 in Table 2 should be T and G, respectively. This error leads to changes in the direction of the Mendelian randomization estimates for FGF21 in Table 3 (i.e., the negative beta estimates were changed to being positive and vice versa) and corresponding changes in the text. The error does not lead to any changes in the P values. >.
Article info
Publication history
Published online: April 05, 2023
Identification
Copyright
© 2023 The Author(s). Published by Elsevier Inc.
User license
Creative Commons Attribution (CC BY 4.0) | How you can reuse 
Elsevier's open access license policy
Creative Commons Attribution (CC BY 4.0)
Permitted
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article
- Reuse portions or extracts from the article in other works
- Sell or re-use for commercial purposes
Elsevier's open access license policy
ScienceDirect
Access this article on ScienceDirectLinked Article
- Genome-wide association and Mendelian randomization study of fibroblast growth factor 21 reveals causal associations with hyperlipidemia and possibly NASHMetabolism - Clinical and ExperimentalVol. 137
- PreviewFibroblast growth factor 21 (FGF21) is a hepatokine that produces metabolic benefits, such as improvements of lipid profile. We performed a genome-wide association study (GWAS) to identify genetic variants associated with circulating FGF21 and investigated the causal effects of FGF21 on pertinent outcomes using Mendelian randomization (MR).
- Full-Text
- Preview
